[Unspecific effects of certain siRNA molecules used in the treatment of age related macular degeneration].
In clinical trials on age-related macular degeneration, small interfering RNAs (siRNAs) targeting vascular endothelial growth factor or its receptor are used to inhibit angiogenesis. However, novel data suggests that certain siRNA molecules can act unspecifically, without even entering a cell. The sequence- and target-independent suppression of the angiogenesis seems to be mediated via extracellular binding to the toll-like receptors TLR3.
Ebbesen
Mette
M
Aarhus Universitet, Center for Bioetik og Nanoetik, Denmark.
Bek
Toke
T
Pedersen
Finn Skou
FS
Jensen
Thomas G
TG
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D000069579:Ranibizumab; D051196:Toll-Like Receptor 3 / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000235:genetics
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D034741:RNA, Small Interfering; D051196:Toll-Like Receptor 3; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab